Home
Latest
Finance
IPO
ETF
Tech
Overseas
Video
Research
Topic
Download App
简
繁
简
繁
EN
Home
Latest
Finance
IPO
ETF
Tech
Overseas
Video
Research
Topic
HOME
·
01276.HK
HENGRUI PHARMA (01276.HK): HRS-1597 tablets approved for clinical trial for weight management
Tags:
HENGRUI PHARMA
01276.HK
Clinical Trial
2026-09-07
HENGRUI PHARMA (01276.HK): SHR-1179 injection approved for clinical trial, targeting weight management indication
Tags:
HENGRUI PHARMA
01276.HK
Clinical Trial
2026-09-07
HENGRUI PHARMA (01276.HK): NMPA approves oteseconazole capsules for marketing in China for severe vulvovaginal candidiasis
Tags:
HENGRUI PHARMA
01276.HK
Drug Marketing Authorization
2026-09-04
HENGRUI PHARMA (01276.HK): NMPA accepts marketing application for atopic dermatitis antibody Zhuotuoqibai injection
Tags:
HENGRUI PHARMA
01276.HK
New Drug Marketing Application
2026-09-04
HENGRUI PHARMA (01276.HK): NMPA accepts marketing application for oral GLP-1 weight-loss drug HRS-7535 tablets
Tags:
HENGRUI PHARMA
01276.HK
R&D Progress
2026-09-04
Hengrui Pharmaceuticals (01276.HK): NDA for HRG2010 Capsules Accepted
Tags:
Hengrui Pharmaceuticals
01276.HK
2026-08-25
HENGRUI PHARMA (01276.HK): SHR-7012 Injection Receives Clinical Trial Approval for Treating Cutaneous Lupus Erythematosus
Tags:
HENGRUI PHARMA
01276.HK
R&D Progress
2026-08-20
HENGRUI PHARMA(01276.HK): 2026 Interim Report - Profit Attributable to Shareholders stood at CNY 4.47 billion, YoY increase of 0.34%
Tags:
HENGRUI PHARMA
01276.HK
profit
2026-08-20
HENGRUI PHARMA (01276.HK): Proposes Adoption of 2026 H-Share Scheme with Mandate Limit of Not More Than 1,000,000 H Shares
Tags:
HENGRUI PHARMA
01276.HK
Share Scheme
2026-08-19
HENGRUI PHARMA (01276.HK): SHR-7590 Injection Receives Drug Clinical Trial Approval Notice for Ulcerative Colitis and Crohn's Disease
Tags:
HENGRUI PHARMA
01276.HK
R&D Progress
2026-08-12
HENGRUI PHARMA (01276.HK): HRS-4729 Injection Approved for Phase II Clinical Trial in Type 2 Diabetes
Tags:
HENGRUI PHARMA
01276.HK
R&D Progress
2026-08-12
HENGRUI PHARMA (01276.HK): Trastuzumab Rezetecan Approved for Third Indication, Becoming China's First Anti-HER2 Product Approved for Colorectal Cancer
Tags:
HENGRUI PHARMA
01276.HK
Indications approved
2026-08-06
HENGRUI PHARMA (01276.HK): Class 1 Innovative Drug Ivarmacitinib Sulfate Tablets Approved for Fifth Indication, Completing Full-Disease-Spectrum Coverage of Axial Spondyloarthritis
Tags:
HENGRUI PHARMA
01276.HK
biopharmaceutical
2026-08-06
HENGRUI PHARMA(01276.HK): SHR‑A2009 for Injection Combined with Adebrelimab Obtains NMPA Clinical Trial Approval for Non‑Small‑Cell Lung Cancer
Tags:
HENGRUI PHARMA
01276.HK
Clinical Trial
2026-08-04
Metis TechBio-P (07666.HK): AiTEM AI Formulation Platform Partners with HENGRUI PHARMA to Accelerate Drug Formulation Development
Tags:
METIS TECHBIO-P
07666.HK
HENGRUI PHARMA
01276.HK
AiTEM
2026-08-03
Jiangsu Hengrui Pharmaceuticals (01276.HK): HRS5580 for Injection Obtains Clinical Trial Approval Notice
Tags:
Jiangsu Hengrui Pharmaceuticals
01276.HK
2026-07-30
Jiangsu Hengrui Pharmaceuticals (01276.HK): Insulin Sudelidec Injection Approved for Marketing by NMPA
Tags:
Jiangsu Hengrui Pharmaceuticals
01276.HK
2026-07-30
Hengrui Pharmaceuticals (01276.HK): SHR-4375 Injection Granted FDA Orphan Drug Designation
Tags:
Hengrui Pharmaceuticals
01276.HK
2026-07-28
Hengrui Pharmaceuticals (01276.HK): HRS-1780 Tablets Obtains Clinical Trial Approval Notice
Tags:
Hengrui Pharmaceuticals
01276.HK
2026-07-28
Hengrui Pharmaceuticals(01276.HK): Injection HRS9531 Obtains Clinical Trial Approval Notice
Tags:
Hengrui Pharmaceuticals
01276.HK
2026-07-16
Previous
1
2
3
Next
Finance
METIS TECHBIO-P (07666.HK): plans H-share buyback of up to HKD 300m
Finance
HENGRUI PHARMA (01276.HK): hetrombopag NDA accepted in China
Research
HK Stock Connect Daily: NETEASE -17.60% on Gaming Slump - 20261120
Finance
WATER OASIS GP (01161.HK): FY profit seen doubling to HKD 165-175m
Research
HK AI Concept Stock Daily: BABA-W +3.48% Defies Slump - 20261120
Research
Hong Kong Recently Listed Stocks Daily Report: BRAINAURORA-B Rises 39.50% to Lead; Intelligent Driving and Smart Parking Gain Traction-20261120
Finance
NewTimeSpace | HK Close: HSI -1.89%, Semis and Hardware Lead Declines
Research
HK shares ETFs Daily Report: Fubon Taiwan Semiconductor ETF Falls 9.81% as CSI 300 and India Themes Rise-Nov 20, 2026
Research
Offshore Trust Insight | NIO-SW (09866.HK) -5.07%; Users Trust 50m
Research
HK Stock Connect Insight | RA MATERIALS (09607.HK) -13.26%; Stake Rise
Scan QR Code
Download App